Non-small cell lung cancer
Conditions
Interventions
control group:Xihuang Jiedu capsule placebo
experimental group:Xihuang Jiedu capsule
Sponsors
Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with stage II-IIIA non-small cell lung cancer (NSCLC) after surgery confirmed by pathology or cytology. 2. Disease-free patients after adjuvant postoperative treatment. Enroll within 52 days after the last chemotherapy drug administration; or for those who have completed neoadjuvant chemotherapy before surgery enroll within 1 month after the end of surgical treatment. 3. Have completed at least 4 cycles of the adjuvant chemotherapy regimen specified in the NCCN guidelines. 4. Age between 18 and 75 years old. 5. Performance status score (ECOG): 0 - 1 point. 6. Expected survival period = 6 months. 7. The subjects have no severe dysfunction of major organs such as the liver kidneys and heart.
Exclusion criteria
Exclusion criteria: 1. Patients receiving targeted therapy; 2. Patients with adenocarcinoma and confirmed Ex19del/L858R (+); 3. Patients currently participating in other clinical trials; 4. Patients who have a fertility plan within one year are pregnant or are breastfeeding; 5. Patients who cannot cooperate with follow-up; 6. Patients allergic to the study drug; 7. Any situation that may prevent the subject from completing the follow-up process including but not limited to severe and difficult-to-control organic diseases or infections unstable angina pectoris congestive heart failure etc.; patients with severe liver and kidney function abnormalities; patients with symptomatic and difficult-to-control neurological or mental diseases or mental disorders; patients with uncontrolled central nervous system metastases obvious intracranial hypertension or neuropsychiatric symptoms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year disease-free survival rate;1-year disease-free survival rate;clinical symptom;quality of life;overall survival; | — |
Countries
China
Contacts
Public ContactHou Wei
Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine
Outcome results
None listed